Lack of demand forces uniQure to bail on gene therapy Glybera, marketing authorization in Europe to expire October 25 – Seeking Alpha
|
Lack of demand forces uniQure to bail on gene therapy Glybera, marketing authorization in Europe to expire October 25
Seeking Alpha Citing a lack of demand, uniQure (NASDAQ:QURE) announces that it will not pursue a renewal of its European marketing authorization for Glybera (alipogene tiparvovec), set to expire on October 25. The European Commission OK'd the gene therapy for an … uniQure Announces It Will Not Seek Marketing Authorization Renewal for Glybera in Europe Glybera Marketing Authorization Application Withdrawn In Europe and Other Selected Countries |
